Kintara Therapeutics Analyst Ratings
Kintara Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/14/2023 | 204.35% | Maxim Group | → $14 | Upgrades | Hold → Buy |
| 09/29/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 05/16/2022 | — | Dawson James | Downgrades | Buy → Neutral | |
| 01/20/2022 | -34.78% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 09/30/2021 | 8.7% | Aegis Capital | $7 → $5 | Maintains | Buy |
| 09/28/2021 | 30.43% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 02/03/2021 | 52.17% | Aegis Capital | $6 → $7 | Maintains | Buy |
| 09/14/2020 | 30.43% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/14/2023 | 204.35% | Maxim 集團 | → 14 美元 | 升級 | 持有 → 買入 |
| 2022 年 9 月 29 日 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 05/16/2022 | — | 道森·詹姆斯 | 降級 | 買入 → 中性 | |
| 01/20/2022 | -34.78% | HC Wainwright & Co. | 6 美元 → 3 美元 | 維護 | 買 |
| 09/30/2021 | 8.7% | 宙斯盾資本 | 7 美元 → 5 美元 | 維護 | 買 |
| 2021 年 9 月 28 日 | 30.43% | HC Wainwright & Co. | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/03/2021 | 52.17% | 宙斯盾資本 | 6 美元 → 7 美元 | 維護 | 買 |
| 2020 年 9 月 14 日 | 30.43% | 宙斯盾資本 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Kintara Therapeutics (KTRA)?
Kintara Therapeutics（KTRA）的目標價格是多少？
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on July 14, 2023. The analyst firm set a price target for $14.00 expecting KTRA to rise to within 12 months (a possible 204.35% upside). 2 analyst firms have reported ratings in the last year.
Maxim集團於2023年7月14日公佈了金塔拉療法（納斯達克股票代碼：KTRA）的最新目標股價。該分析公司將目標股價定爲14.00美元，預計KTRA將在12個月內升至12個月內（可能上漲204.35％）。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Kintara Therapeutics (KTRA)?
Kintara Therapeutics（KTRA）的最新分析師評級是多少？
The latest analyst rating for Kintara Therapeutics (NASDAQ: KTRA) was provided by Maxim Group, and Kintara Therapeutics upgraded their buy rating.
Maxim集團對Kintara Therapeutics（納斯達克股票代碼：KTRA）的最新分析師評級由Maxim集團提供，Kintara Therapeutics上調了買入評級。
When is the next analyst rating going to be posted or updated for Kintara Therapeutics (KTRA)?
Kintara Therapeutics（KTRA）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kintara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kintara Therapeutics was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Kintara Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Kintara Therapeutics的最新評級是在2023年7月14日公佈的，因此您應該預計下一個評級將在2024年7月14日左右公佈。
Is the Analyst Rating Kintara Therapeutics (KTRA) correct?
分析師對Kintara Therapeutics（KTRA）的評級是否正確？
While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $4.60, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Kintara Therapeutics（KTRA）評級已上調，目標股價爲0.00美元，至14.00美元。Kintara Therapeutics（KTRA）目前的交易價格爲4.60美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。